Welcome to our dedicated page for Avenue Therapeutics news (Ticker: $ATXI), a resource for investors and traders seeking the latest updates and insights on Avenue Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avenue Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avenue Therapeutics's position in the market.
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) announced the entry into warrant exercise agreements with existing accredited investors for the immediate exercise of certain outstanding warrants to purchase an aggregate of 16.5 million shares of the Company’s common stock. The gross proceeds to Avenue from the exercise of the warrants are expected to be approximately $5.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.44%
Tags
-
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) has finalized an agreement with the FDA for the Phase 3 safety study protocol of IV tramadol for the treatment of acute post-operative pain. The study aims to address the theoretical risk of opioid-induced respiratory depression and is expected to be completed within 12 months. The company plans to initiate the study soon, potentially leading to FDA approval and improving the current treatment paradigm for U.S. patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
95.43%
Tags
-
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) has announced that all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA), with topline data anticipated in the second quarter of 2024. The 12-week trial enrolled 25 patients, randomly assigned to AJ201 (600 mg/day) or placebo, with the primary endpoint being the assessment of safety and tolerability of AJ201 in subjects with clinically and genetically defined SBMA. Secondary endpoints include various biomarkers addressing proof of target engagement, including changes in mutant androgen receptor protein levels in skeletal muscle and changes in fat and muscle composition as seen on MRI scans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) announced that Dr. Amy Chappell will present preclinical data for BAER-101 at the AES 2023 Annual Meeting. The data demonstrate the molecule's potential to significantly suppress seizures in a translational animal model of absence epilepsy. BAER-101 selectively targets GABAA α2 and α3 subtypes, potentially improving anticonvulsant and anxiolytic activity while minimizing the risk of tolerance and abuse. The molecule underwent preclinical evaluation in the GAERS model, demonstrating full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg, PO. The safety, tolerability, and efficacy data support BAER-101's continued development in a Phase 2a trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.43%
Tags
-
News
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) reported financial results and recent corporate highlights for the third quarter ended September 30, 2023. The company's Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA) remains on track to report topline data in the second quarter of 2024. Positive BAER-101 preclinical data has been accepted for presentation at the American Epilepsy Society Annual Meeting. Avenue also reached an agreement with the U.S. FDA on the study design and analysis approach for the Phase 3 safety study of IV tramadol. The company raised $5 million in gross proceeds from a public equity offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
-
Rhea-AI Summary
Avenue Therapeutics, Inc. has closed its public offering, raising approximately $5.0 million. The offering consisted of 16,633,400 units at a price of $0.3006 per unit. Each unit included one share of common stock, one Series A warrant, and one Series B warrant. Maxim Group LLC and Lake Street Capital Markets, LLC acted as placement agents for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
Rhea-AI Summary
Avenue Therapeutics, Inc. has announced the pricing of its public offering of 16,633,400 units at a price of $0.3006 per unit. Each unit consists of one share of common stock, one Series A warrant, and one Series B warrant. The gross proceeds from the offering are expected to be approximately $5.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.05%
Tags
-
Rhea-AI Summary
Avenue Therapeutics CEO to present corporate update at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
-
News
Rhea-AI Summary
Avenue Therapeutics reports progress in clinical trials and agreement with FDA on study design for IV tramadol. First patient dosed in Phase 1b/2a trial of AJ201 for SBMA. Positive preclinical data for BAER-101 in epilepsy. Financial results show decrease in cash and increase in expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
Rhea-AI Summary
Avenue Therapeutics announces positive preclinical results for BAER-101 in epilepsy treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
Avenue Therapeutics, Inc.
Nasdaq:ATXI
ATXI Rankings
ATXI Stock Data
3.51M
39.44M
10.88%
2.8%
0.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
BAY HARBOR ISLANDS
About ATXI
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.